Atlas Trials

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Clinical trial NCT07435324 · COMPLETED

Trial details

NCT number
NCT07435324
Sponsor
R-Pharm
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Head and Neck Squamous Cell Carcinoma
Start date
2024-08-08
Primary completion
2025-09-16
Enrollment
161

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.